Categories AlphaGraphs, Earnings, Health Care
Gilead Sciences reports Q3 earnings. Here’s everything you need to know
Gilead Sciences, Inc. (NASDAQ: GILD), a leading research-based biopharmaceutical company, on Tuesday reported financial results for the third quarter of 2023.
Revenues came in at $7.05 billion in the September quarter, compared to $7.04 billion in the corresponding period of 2022. For fiscal 2023, the company expects product revenues to be in the range of $26.7 billion to $26.9 billion.
Adjusted net income was $2.29 per share in the third quarter, vs. $1.90 per share in the prior-year period. The company reported an unadjusted profit of $2.18 billion or $1.75 per share for the quarter, compared to $1.79 billion or $1.43 per share in Q3 2022.
Prior Performance
Listen to the conference calls as they happen. Don't miss a beat! With AlphaStreet Intelligence, you can listen to live calls and interviews as they happen, so you never have to worry about missing out on important information.
Most Popular
CVX Earnings: Chevron reports lower revenue and profit for Q1 2024
Energy exploration company Chevron Corporation (NYSE: CVX) announced first-quarter 2024 financial results, reporting a decline in net profit and revenues. Net income attributable to Chevron Corporation was $5.50 billion or
ABBV Earnings: AbbVie reports lower adj. profit for Q1 2024; revenue edges up
Specialty biopharmaceutical company AbbVie, Inc. (NYSE: ABBV) Friday announced first-quarter 2024 financial results, reporting a decline in adjusted earnings and a modest rise in revenues. The company reported worldwide net
CL Earnings: Key quarterly highlights from Colgate-Palmolive’s Q1 2024 financial results
Colgate-Palmolive Company (NYSE: CL) reported first quarter 2024 earnings results today. Net sales increased 6.2% year-over-year to $5.06 billion. Organic sales increased 9.8%. Net income attributable to Colgate-Palmolive Company was